In general, the more mutations (i.e., the higher the TMB), the greater the likelihood that neoantigens presented by MHC proteins will be immunogenic, which aids T cells in recognizing and eliminating carcinoma cells (Rooney et al., 2015; Chabanon et al., 2016). This evidence concerns the gene HLA-C and carcinoma.